River Global Investors LLP Acquires 5,030 Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

River Global Investors LLP grew its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 31.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 21,084 shares of the medical equipment provider's stock after buying an additional 5,030 shares during the period. River Global Investors LLP's holdings in Zimmer Biomet were worth $2,276,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of ZBH. Price T Rowe Associates Inc. MD boosted its stake in Zimmer Biomet by 12.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock worth $1,404,638,000 after purchasing an additional 1,215,935 shares in the last quarter. American Century Companies Inc. boosted its stake in Zimmer Biomet by 12.6% in the 2nd quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Boston Partners boosted its stake in Zimmer Biomet by 26.3% in the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock worth $437,413,000 after purchasing an additional 691,191 shares in the last quarter. Magnetar Financial LLC boosted its stake in Zimmer Biomet by 58.7% in the 2nd quarter. Magnetar Financial LLC now owns 1,310,265 shares of the medical equipment provider's stock worth $142,203,000 after purchasing an additional 484,816 shares in the last quarter. Finally, Van ECK Associates Corp raised its position in Zimmer Biomet by 12.4% in the 3rd quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock worth $391,239,000 after buying an additional 411,163 shares during the last quarter. Institutional investors own 88.89% of the company's stock.

Zimmer Biomet Stock Performance

Zimmer Biomet stock traded down $0.51 during midday trading on Friday, hitting $108.18. The stock had a trading volume of 1,175,736 shares, compared to its average volume of 1,472,302. The firm's fifty day moving average is $106.37 and its two-hundred day moving average is $110.40. The company has a market capitalization of $21.54 billion, a PE ratio of 20.57, a P/E/G ratio of 1.99 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 52-week low of $101.47 and a 52-week high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last released its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.65 EPS. On average, research analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were paid a $0.24 dividend. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.89%. Zimmer Biomet's payout ratio is 18.25%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on ZBH shares. Oppenheimer decreased their target price on Zimmer Biomet from $145.00 to $135.00 and set an "outperform" rating for the company in a research report on Tuesday, October 15th. Morgan Stanley decreased their target price on Zimmer Biomet from $130.00 to $120.00 and set an "equal weight" rating for the company in a research report on Monday, July 15th. BTIG Research decreased their target price on Zimmer Biomet from $134.00 to $126.00 and set a "buy" rating for the company in a research report on Thursday, October 3rd. Needham & Company LLC reissued a "hold" rating on shares of Zimmer Biomet in a research report on Thursday, October 31st. Finally, Robert W. Baird decreased their target price on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a research report on Thursday, August 8th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating and eight have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $124.11.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.